(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 21.7% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 11.73%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Dexcom's revenue in 2023 is $2,792,800,000.On average, 8 Wall Street analysts forecast DXCM's revenue for 2023 to be $1,347,303,489,489, with the lowest DXCM revenue forecast at $1,305,790,783,763, and the highest DXCM revenue forecast at $1,409,919,407,875. On average, 4 Wall Street analysts forecast DXCM's revenue for 2024 to be $1,593,821,922,543, with the lowest DXCM revenue forecast at $1,518,360,217,694, and the highest DXCM revenue forecast at $1,665,904,255,056.
In 2025, DXCM is forecast to generate $1,856,375,861,656 in revenue, with the lowest revenue forecast at $1,856,375,861,656 and the highest revenue forecast at $1,856,375,861,656.